IP Library Granted Patent US 9,084,805
Granted Patent B2
US 9,084,805 · App. 12/991,589 · Granted Jul 21, 2015

Sialic acid to support the immune system in the elderly

Inventors: Nobert Sprenger (Savigny, CH); Karine Vidal (Lausanne, CH); Christine Cherbut (Pully, CH)
Assignee: Nestec S.A.
A61K31/7012A23L1/30A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,084,805
App. No.
12/991,589
Granted
Jul 21, 2015
Kind
B2
Abstract

The present invention generally relates to the field of the immune system, in particular to strengthening the immune system of the elderly. One embodiment of the present invention relates to the use of a food product enriched with sialic acid for the preparation of a composition to strengthen the immune system.

Claims (18)

1. A method for treating a disorder linked to an alteration of the immune system selected from the group consisting of infections, autoimmune-like diseases, innate defence disorders, cyclic neutropenia, and combinations thereof, the method comprising administering a therapeutically-effective amount of a composition containing a protein fraction comprising N-acetylneuraminic acid bound to a threonine rich peptide/protein backbone to an individual having same, the protein fraction comprises at least one glycosylated amino acid or peptide selected from the group consisting of NeuAc-α-2,3-Gal-β-1,3-(NeuAc-α-2,6-)-GalNAc-R n , NeuAc-α-2,3-Gal-β-1,3-GalNAc-R n , Gal-β-1,3-(NeuAc-α-2,6-)-GalNAc-R n , and Gal-β-1,3-GalNAc-R n , wherein R is an amino acid residue and n has a value between 1 and 10; if n has a value of 1, R is a threonine residue or a serine residue; and if n has a value of 2 to 10, the peptide contains at least one threonine or serine residue, and at least 15 mol % of the ingredient is N-acetyl-neuraminic acid.

2. The method of claim 1 , wherein the protein fraction comprises about 7 to 25% by weight N-acetylneuraminic acid and threonine in an amount of between about 8 and 22% of the total number of amino acids.

3. The method of claim 1 wherein the disorder is linked to an impaired cell mediated immune response.

4. The method of claim 1 , wherein the alteration of the immune system is selected from the group consisting of infections, innate defence disorders, cyclic neutropenia; and combinations thereof.

5. The method of claim 1 for producing a vaccine response stimulating effect.

6. The method of claim 1 , wherein the composition treats infectious diseases.

7. The method of claim 1 , wherein the composition is in a form selected from the group consisting of a pharmaceutical composition, and a food product.

8. The method of claim 1 , wherein the composition comprises an ingredient selected from the group consisting of another immune boosting agent and a probiotic.

9. The method of claim 1 , wherein the composition comprises a fraction selected from the group consisting of a fat fraction and a carbohydrate fraction.

10. The method of claim 1 , wherein the composition comprises an ingredient selected from the group consisting of a pain relieving agent, a stabilizing agent, a flavouring agent, a colouring agent, a lubricant, and a prebiotic.

11. The method of claim 1 , wherein the composition is intended for humans or pets.

12. The method of claim 1 , wherein the N-acetylneuraminic acid is present in the composition in an amount of 1 mg to 250 mg/g dry weight of the composition.

13. The method of claim 1 , wherein the N-acetylneuraminic acid is to be administered in a daily amount of 1 mg to 2 g /kg body weight of the subject to be treated.

14. The method of claim 1 , wherein the composition is selected from the group consisting of milk powder based products; instant drinks; ready-to-drink formulations; nutritional powders; nutritional liquids; milk-based products; cereal products;

beverages; water; coffee; cappuccino; malt drinks; chocolate flavoured drinks; culinary products;

soups; topical creams; suppositories; tablets; syrups, and formulations for transdermal applications.

15. The method of claim 1 to be administered to the elderly.

16. The method of claim 1 , comprising co-administering the composition with a vaccine.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0001 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0165 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ENGLISH TRANSLATION TO SHOW THE FULL AND CORRECT NEW NAME IN SECTION 51. PREVIOUSLY RECORDED AT REEL: 049391 FRAME: 0756. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER. Recorded Jun 13, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049853/0398 →
MERGER Recorded Jun 6, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049391/0756 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 21, 2011
From: SPRENGER, NORBERT; VIDAL, KARINE; CHERBUT, CHRISTINE
To: NESTEC S.A.
Reel/Frame 025678/0569 →
Priority Claims (1)
EP 08155855 · May 8, 2008 · regional
Continuity (1)
Related Publication 20110189219A1 · Aug 4, 2011